Amyloid PET disclosure in subjective cognitive decline: Patient experiences over time.
| Autor: | Hendriksen HMA; Alzheimer Center Amsterdam, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands., de Rijke TJ; Medical Psychology, Amsterdam UMC location AMC, University of Amsterdam, Amsterdam, the Netherlands.; Amsterdam Public Health, Quality of Care, Personalized Medicine, Amsterdam, the Netherlands., Fruijtier A; Alzheimer Center Amsterdam, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.; Medical Psychology, Amsterdam UMC location AMC, University of Amsterdam, Amsterdam, the Netherlands.; Amsterdam Public Health, Quality of Care, Personalized Medicine, Amsterdam, the Netherlands., van de Giessen E; Department of Radiology & Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.; Amsterdam Neuroscience, Brain Imaging, Amsterdam, the Netherlands., van Harten AC; Alzheimer Center Amsterdam, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands., van Leeuwenstijn-Koopman MSSA; Alzheimer Center Amsterdam, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands., van der Schaar J; Alzheimer Center Amsterdam, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands., Trieu C; Alzheimer Center Amsterdam, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands., Visser D; Department of Radiology & Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.; Amsterdam Neuroscience, Brain Imaging, Amsterdam, the Netherlands., Smets EMA; Medical Psychology, Amsterdam UMC location AMC, University of Amsterdam, Amsterdam, the Netherlands.; Amsterdam Public Health, Quality of Care, Personalized Medicine, Amsterdam, the Netherlands., Visser LNC; Alzheimer Center Amsterdam, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.; Medical Psychology, Amsterdam UMC location AMC, University of Amsterdam, Amsterdam, the Netherlands.; Amsterdam Public Health, Quality of Care, Personalized Medicine, Amsterdam, the Netherlands.; Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden., van der Flier WM; Alzheimer Center Amsterdam, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.; Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Sep; Vol. 20 (9), pp. 6556-6565. Date of Electronic Publication: 2024 Aug 01. |
| DOI: | 10.1002/alz.14148 |
| Abstrakt: | Introduction: We disclosed amyloid positron emission tomography (PET) results in individuals with subjective cognitive decline (SCD) and studied patient experiences and outcomes over a 6-month period. Methods: Fifty-seven participants from the Subjective Cognitive Impairment Cohort (SCIENCe) (66 ± 8 years, 21 [37%] F, Mini-Mental State Examination 29 ± 1, 15 [26%] amyloid positive [A+]) completed questionnaires 1 week prior (T0), 1 day after (T1), and 6 months after amyloid PET disclosure (T2). Questionnaires addressed patient-reported experiences and outcomes. Results: Independent of amyloid status, participants were satisfied with the consultation (scale 1-10; 7.9 ± 1.7) and information provided (scale 1-4; T1: 3.3 ± 0.9, T2: 3.2 ± 0.8). After 6 months, A+ participants reported more information needs (45% vs. 12%, p = 0.02). Independent of amyloid status, decision regret (scale 1-5; A+: 1.5 ± 0.9, A-: 1.4 ± 0.6, p = 0.53) and negative emotions (negative affect, uncertainty, anxiety) were low (all p > 0.15 and P Discussion: Participants with SCD valued amyloid PET disclosure positively, regardless of amyloid status. The need for information after 6 months, which was stronger in A+ individuals, underscores the importance of follow-up. Highlights: Participants with subjective cognitive decline (SCD) positively valued amyloid positron emission tomography (PET) disclosure. Participants with SCD experienced low levels of decision regret. We did not observe an increase in negative emotions. After 6 months, amyloid-positive individuals wanted more information. (© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Plný text